Table 1.

Demographic and clinical data for the cohort of 2D-T1 non-progressors with available week 2, week 8 or week 16 DSC-MRI data.

Subject	Age	Sex	KPS	Type of Surgery (Initial GBM)	Additional Surgery (Recurrent GBM)	Location of Primary Tumor								Treatment arm	Week 2 DSC-MRI (n=13)	Week 8 DSC-MRI (n=15)	Week 16 DSC-MRI (n=8)
						Frontal	Temporal	Parietal	Occipital	Basal Ganglia	Cerebellum	Brainstem	Corpus Callosum
1	55	Male	90	Subtotal resection	None		X							Bev+CPT-11	0	1	0
2	45	Male	100	Total Tumor Resection	None		X	X						Bev+CPT-11	0	1	0
3	51	Female	80	Total Tumor Resection	Total Tumor Resection		X							Bev+CPT-11	0	1	1
4	48	Female	70	Subtotal resection	None	X								Bev+TMZ	0	1	1
5	36	Male	100	Total Tumor Resection	None		X	X	X					Bev+CPT-11	0	1	1
6	62	Male	70	Missing	None	X								Bev+CPT-11	0	1	1
7	58	Male	100	Total Tumor Resection	Total Tumor Resection			X						Bev+TMZ	1	0	0
8	39	Male	80	Total Tumor Resection	None		X	X		X		X	X	Bev+CPT-11	1	0	0
9	74	Female	100	Biopsy only	None		X	X	X		X			Bev+CPT-11	1	0	0
10	68	Female	80	Total Tumor Resection	None		X							Bev+TMZ	1	0	0
11	64	Male	90	Total Tumor Resection	None		X	X	X				X	Bev+TMZ	1	1	0
12	60	Female	80	Subtotal resection	Subtotal Resection		X	X						Bev+CPT-11	1	1	0
13	43	Female	70	Total Tumor Resection	None	X		X					X	Bev+CPT-11	1	1	0
14	60	Male	90	Total Tumor Resection	Total Tumor Resection		X		X					Bev+TMZ	1	1	0
15	62	Female	100	Subtotal resection	None		X	X						Bev+TMZ	1	1	0
16	23	Male	70	Subtotal resection	None	X								Bev+CPT-11	1	1	1
17	58	Female	80	Total Tumor Resection	Total Tumor Resection	X								Bev+CPT-11	1	1	1
18	43	Male	100	Total Tumor Resection	None			X						Bev+TMZ	1	1	1
19	51	Male	70	Biopsy only	None	X								Bev+TMZ	1	1	1

KPS, Karnofsky Performance Status; GBM, Glioblastoma Multiforme; DSC-MRI, Dynamic Susceptibility Contrast MR Perfusion; Bev, Bevacizumb; TMZ, Temozolomide; CPT-11, Irinotecan.

The "X" designates which of the 8 identified brain regions were involved with tumor for the particular case.